Mariam Tolba, Michael Zhang, Jonathan K Duh, Linda Liverani, Julia Chang, Nucharin Supakul, Robert M Lober, Samuel H Cheshier, Sarah A Mattonen, Alok Jaju, Laura M Prolo, Kristen W Yeom
{"title":"MRI-based radiomics for prognosis of non-midline, pediatric high-grade gliomas.","authors":"Mariam Tolba, Michael Zhang, Jonathan K Duh, Linda Liverani, Julia Chang, Nucharin Supakul, Robert M Lober, Samuel H Cheshier, Sarah A Mattonen, Alok Jaju, Laura M Prolo, Kristen W Yeom","doi":"10.1007/s11060-026-05785-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Non-midline, pediatric high-grade gliomas (HGG) represent one of the leading causes of cancer-related deaths in children with underlying molecular genetics and driver mutations that are distinct from adult HGGs. Image-based biomarkers that assist pediatric HGG risk-stratification could potentiate treatment strategies. Towards this, we investigated radiomics approaches for non-midline pediatric HGG prognosis.</p><p><strong>Methods: </strong>We identified 77 children (mean age: 140 months; 43 males) with non-midline-origin, hemispheric pediatric HGG tumors across five pediatric institutions. We extracted 1800 image-biomarker standardization initiative (IBSI)-based radiomics tumor features from treatment-naïve, axial gadolinium-enhanced axial T1- and axial T2-weighted brain MRI (Gad T1-MRI, T2-MRI). We performed k-fold cross validation and Cox regression to identify optimal predictive features of overall survival. We calculated the risk scores for each patient using a linear combination of the selected features weighted by their coefficients determined by the Cox regression model. Patients were stratified based on the median risk score into high- and low-risk groups. Python (version 3.10.0) was used for all model development.</p><p><strong>Results: </strong>The Cox regression model that included both clinical (age and sex) and MRI-derived radiomics features demonstrated a concordance of 0.78 (95% CI: 0.70-0.83) compared to concordance of 0.75 (95% CI: 0.69-0.82) that used radiomics features alone and concordance of 0.61 (95% CI: 0.54-0.67) that used clinical features (age and sex) alone. Using the risk scores derived from our radiomics model, we present a Kaplan-Meier curve on our HGG cohort. Median overall survival was 21.7 months in the high-risk group and 44.6 months in the low-risk group (log-rank P = 0.007; hazard ratio 2.42, 95% CI 1.26-4.66).</p><p><strong>Conclusion: </strong>In this multi-center, pilot study, we identified optimal radiomics features in the creation of a prognostic pediatric HGG model. Computational MRI techniques may offer new approaches for quantitatively evaluating tumor phenotype and serve a potential future role in therapy planning and clinical trials eligibility.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"179 3","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-026-05785-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Non-midline, pediatric high-grade gliomas (HGG) represent one of the leading causes of cancer-related deaths in children with underlying molecular genetics and driver mutations that are distinct from adult HGGs. Image-based biomarkers that assist pediatric HGG risk-stratification could potentiate treatment strategies. Towards this, we investigated radiomics approaches for non-midline pediatric HGG prognosis.
Methods: We identified 77 children (mean age: 140 months; 43 males) with non-midline-origin, hemispheric pediatric HGG tumors across five pediatric institutions. We extracted 1800 image-biomarker standardization initiative (IBSI)-based radiomics tumor features from treatment-naïve, axial gadolinium-enhanced axial T1- and axial T2-weighted brain MRI (Gad T1-MRI, T2-MRI). We performed k-fold cross validation and Cox regression to identify optimal predictive features of overall survival. We calculated the risk scores for each patient using a linear combination of the selected features weighted by their coefficients determined by the Cox regression model. Patients were stratified based on the median risk score into high- and low-risk groups. Python (version 3.10.0) was used for all model development.
Results: The Cox regression model that included both clinical (age and sex) and MRI-derived radiomics features demonstrated a concordance of 0.78 (95% CI: 0.70-0.83) compared to concordance of 0.75 (95% CI: 0.69-0.82) that used radiomics features alone and concordance of 0.61 (95% CI: 0.54-0.67) that used clinical features (age and sex) alone. Using the risk scores derived from our radiomics model, we present a Kaplan-Meier curve on our HGG cohort. Median overall survival was 21.7 months in the high-risk group and 44.6 months in the low-risk group (log-rank P = 0.007; hazard ratio 2.42, 95% CI 1.26-4.66).
Conclusion: In this multi-center, pilot study, we identified optimal radiomics features in the creation of a prognostic pediatric HGG model. Computational MRI techniques may offer new approaches for quantitatively evaluating tumor phenotype and serve a potential future role in therapy planning and clinical trials eligibility.
期刊介绍:
The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.